Divaza (Divaza)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsplozenges
Composition:

(per 1 tablet)

Active substances:

Antibodies to the brain-specific protein S-100 affinity purified - 0.006 g *

Antibodies to endothelial NO synthase affinity purified - 0.006 g. *

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

* are applied to lactose in the form of a mixture of three active water-alcohol dilutions of the substance diluted 10012, 10030, 100200 time.

Description:

Tablets are flat-cylindrical with a risk and facet, from white to almost white. On the flat side with the risk of inscription MATERIA MEDICA, on the other flat side there is an inscription DIVAZA.

Pharmacotherapeutic group:An antihypoxic agent, an antioxidant, a nootropic agent, an angioprotective agent
ATX: & nbsp
  • Other psychostimulants and nootropic drugs
  • Other anxiolytics
  • Other peripheral vasodilators
  • Other drugs for the treatment of dementia
    • Pharmacodynamics:

    Combined drug:

    Antibodies to the brain-specific protein S-100 have antioxidant, antihypoxic, neuroprotective, anxiolytic effects. Modify the functional activity of the protein S-100, which carries out conjugation in the brain information and metabolic processes.They have a membrane-effect effect, causing a decrease in the amplitude and suppression of the generation of the action potential; modulate the synaptic plasticity in the limbic structures of the brain, the hippocampus, the reticular formation; contribute to the enhancement of inhibitory effects of GABA in the central nervous system. They exhibit the properties of the sigma 1 receptor agonist in vitro. Inhibit the processes of lipid peroxidation.

    They have a normalizing effect on the integrative activity of the brain, which is manifested by a wide range of balanced psychopharmacological effects: antidepressant, anxiolytic, neuroprotective, anti-asthenic, anti-amnestic.

    Antibodies to endothelial NO synthase increase the activity of the enzyme endothelial NO synthase, restore the production of endothelium nitric oxide (NO), eliminate dysfunction of the endothelium, have an endothelioprotective effect, affect NO-dependent vasodilation.

    Experimentally shown the stimulating effect of Divazy on reparative processes in the focus of ischemic brain damage.

    Joint use of the components of the drug is accompanied by an increase in the neuroprotective activity of antibodies to the protein S-100, strengthening the vegetative stabilizing effect, normalizing the vegetative status, synergistic influence of both components on neuronal plasticity, and, as a result, increasing the resistance of the brain to toxic effects; improves integrative activity and restores interhemispheric connections of the brain, promotes elimination of cognitive impairment, stimulates reparative processes and accelerates the recovery of CNS functions, enhances mental performance, restores learning and memory processes, normalizes somatovegetative manifestations, increases cerebral blood flow. Divaza, like its constituent components, does not have sedative and muscle relaxant action, it does not cause addiction and addiction.

    Pharmacokinetics:

    The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra low doses antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the DIVAZ preparation.

    Indications:Restoring the integrative activity of the brain with a wide range of organic disorders of the central nervous system, including those caused by neurodegenerative diseases, cerebrovascular (including ischemic) diseases, neuroinfections, craniocerebral trauma - as part of complex therapy. Monotherapy of somatoform dysfunction of the autonomic nervous system.
    Contraindications:Increased individual sensitivity to the components of the drug. Divaza is not recommended for use in patients under the age of 18 due to inadequate data on efficacy and safety for this age.
    Pregnancy and lactation:

    The safety of the use of Divaz during pregnancy and lactation has not been studied. If necessary, the drug should take into account the risk / benefit ratio.

    Dosing and Administration:

    Inside. At one time - 1 tablet (keep in your mouth until completely dissolved). Use 1-2 tablets 3 times a day outside meals. Depending on the severity of the condition, in the acute period, the frequency of admission can be increased to 4-6 times a day.

    With pronounced organic lesions of the central nervous system, the duration of the course therapy can reach 4-6 months.

    Side effects:

    Possible reactions of increased individual sensitivity to the components of the drug.

    Overdose:

    In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.

    Interaction:There have been no incidents of incompatibility with other drugs to date.
    Special instructions:The composition of the drug includes lactose, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.
    Effect on the ability to drive transp. cf. and fur:

    Divaza does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

    Form release / dosage:Lozenges.
    Packaging:

    For 20 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil.

    For 1, 2 or 5 contour mesh packages together with the instruction for medical use are placed in a pack of cardboard
    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-006646/10
    Date of registration:09.07.2010 / 11.11.2015
    The owner of the registration certificate:NPF Materia Medica Holding, OOO NPF Materia Medica Holding, OOO Russia
    Manufacturer: & nbsp
    Information update date: & nbsp10.02.16
    Illustrated instructions
      Instructions
      Up